C4 Therapeutics Stock

c4therapeutics.comHealthcareFounded: 2016Funding to Date: $74MM

C4 Therapeutics ("C4T") is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Register for Details

For more details on financing and valuation for C4 Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for C4 Therapeutics.

Register Today

Team

Management Team

Jane Farran Ph.D
Managing Partner
James Bradner MD
Scientific Co-Founder
Andrew Phillips
Chief Executive Officer
Nathanael Gray Ph.D
Co-Founder & Scientific Advisory Board Member
Chris Nasveschuk Ph.D
Vice President, Chemistry
Marc Cohen
Co-Founder & Executive Chairman
Stewart Fisher Ph.D
Chief Scientific Officer
Isabel Chiu Ph.D
Senior Vice President, Strategic Alliances & Product Management
Adam Crystal
Chief Medical Officer

Board Members

Bruce Downey JD
Elena Prokupets Ph.D
Malcolm Salter
Nathanael Gray Ph.D
Ronald Kaiser
Bihua Chen
Cormorant Asset Management
Ken Anderson MD
Miles Stuchin JD
William Scalzulli
The Kraft Family Foundation
Alain Cohen
Cobro Ventures
Jay Eastman Ph.D
EG Capital Group
Marc Cohen
Norman Gretzinger JD
EG Capital Group

Other companies like C4 Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board
C4 Therapeutics has hired Adam Crystal, M.D., Ph.D., a senior director at the Novartis Institutes for BioMedical Research, to be its new chief medical officer and help carry its targeted protein degraders closer to the clinic.